• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Firefly Neuroscience Inc.

    6/23/25 4:55:38 PM ET
    $AIFF
    Computer Software: Prepackaged Software
    Technology
    Get the next $AIFF alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0000803578
    WAVEDANCER, INC.
    INFORMATION ANALYSIS INC
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    FIREFLY NEUROSCIENCE, INC.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
       Over Five Years Ago
    X Within Last Five Years (Specify Year) 2021
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    FIREFLY NEUROSCIENCE, INC.
    Street Address 1 Street Address 2
    1100 MILITARY ROAD
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    KENMORE NEW YORK 14217 888-237-6412

    3. Related Persons

    Last Name First Name Middle Name
    Krzywicki Paul
    Street Address 1 Street Address 2
    1100 Military Road
    City State/Province/Country ZIP/PostalCode
    Kenmore NEW YORK 14217
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Lipschitz Greg
    Street Address 1 Street Address 2
    1100 Military Road
    City State/Province/Country ZIP/PostalCode
    Kenmore NEW YORK 14217
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Issachar Gil
    Street Address 1 Street Address 2
    1100 Military Road
    City State/Province/Country ZIP/PostalCode
    Kenmore NEW YORK 14217
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Menawat Arun
    Street Address 1 Street Address 2
    1100 Military Road
    City State/Province/Country ZIP/PostalCode
    Kenmore NEW YORK 14217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    DeCaprio David
    Street Address 1 Street Address 2
    1100 Military Road
    City State/Province/Country ZIP/PostalCode
    Kenmore HAWAII 14217
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Posner Brian
    Street Address 1 Street Address 2
    1100 Military Road
    City State/Province/Country ZIP/PostalCode
    Kenmore NEW YORK 14217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Vnook Stella
    Street Address 1 Street Address 2
    1100 Military Road
    City State/Province/Country ZIP/PostalCode
    Kenmore NEW YORK 14217
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
    X Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-06-16    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $2,000,000 USD
    or    Indefinite
    Total Amount Sold $1,200,000 USD
    Total Remaining to be Sold $800,000 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    2

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    FIREFLY NEUROSCIENCE, INC. Greg Lipschitz Greg Lipschitz CEO 2025-06-18

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $AIFF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIFF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIFF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Firefly Neuroscience to be Added to the Russell Microcap® Index

      – Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that it will be added to the Russell Microcap® Index as part of this year's reconstitution. The additions will be made effective after the U.S. market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell's U.S. indexe

      6/23/25 8:05:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer's Patients

      – Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology – – Underscores the value of recent Evoke acquisition that builds upon Firefly's FDA-cleared BNA™ AI platform and unique integrated normative reference group – – It's well accepted that earlier dementia course detection can improve outcomes and open up additional treatment opportunities – KENMORE, N.Y., June 20, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intel

      6/20/25 7:45:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

      A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors' earn-out is in Firefly's common stock. The complete corrected press release follows: Builds upon Firefly's recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," or the "Company")

      5/5/25 9:00:00 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Menawat Arun Swarup

      4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

      5/20/25 7:13:48 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by CEO Lipschitz Gregory

      4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

      4/22/25 7:09:21 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 4 filed by President and COO Decaprio David

      4 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)

      4/22/25 7:08:38 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    SEC Filings

    See more
    • SEC Form D filed by Firefly Neuroscience Inc.

      D - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

      6/23/25 4:55:38 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

      6/16/25 4:17:43 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form S-8 filed by Firefly Neuroscience Inc.

      S-8 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)

      5/21/25 9:22:27 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Firefly Neuroscience Inc.

      SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

      9/19/24 9:48:56 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Firefly Neuroscience Inc.

      SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

      8/21/24 6:07:51 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by Firefly Neuroscience Inc.

      SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)

      8/21/24 6:03:49 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Leadership Updates

    Live Leadership Updates

    See more
    • Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman

      TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of current director of the Board, Greg Lipschitz, as Executive Chairman, effective as of December 3, 2024. "I look forward to taking on a more active leadership role as Executive Chairman," said Greg Lipschitz, newly appointed Executive Chairman of Firefly. "I believe that Firefly is uniquely positioned at the intersection of artificial intelligence and brain health that I have l

      12/4/24 9:00:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology
    • Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors

      TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life

      9/5/24 9:00:00 AM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology

    $AIFF
    Financials

    Live finance-specific insights

    See more
    • Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

      Company successfully listed on Nasdaq under the symbol "AIFF" Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering wi

      11/14/24 5:30:18 PM ET
      $AIFF
      Computer Software: Prepackaged Software
      Technology